Top insider buys and sells disclosed for Friday

Enovis Corp. (ENOV) insiders bought shares near a 52-week low, with CEO Damien McDonald acquiring 13,035 shares at $19.10-$19.16. Atara Biotherapeutics (ATRA) director bought 104,166 shares at $9.60. Smith-Midland Corp. (SMID) insiders also made purchases. Illumina (ILMN) director sold $57.2M in shares near a 52-week high. Caris Life Sciences (CRIS) exec sold $14.8M in shares. Okta (OKTA) CFO sold 80,000 shares. Krystal Biotech (KRY) execs sold shares near a 52-week high.

Original reporting
Published Sep 7, 2026, 1:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 7, 2026, 1:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ENOV
Bullish
medium confidence
Mentioned
$ENOV · $ATRA · $SMID · $ILMN · $CRIS · $OKTA
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ENOVBullishLow
01

Why it matters

While some insiders bought at low levels, others sold after strong gains; overall impact is modest.

02

Market read

Insider activity provides limited trading cues; most moves are modest and likely already reflected in price.

03

What to watch

Many purchases are small relative to float; market may already price in insider sentiment.

Relevance 4/10Novelty 4/10Timing: Friday

Background

The article aggregates recent Form 4 insider transactions across several U.S. listed companies.

Company-level read

Ticker impact

$ENOVBullishMedium confidence
Context

CEO Damien McDonald bought 13,035 shares as ENOV trades near its 52‑week low.

Expected impact

Modest upside if buying continues.

Evidence & confidence

Insider purchase at a discount may indicate confidence, but size is modest relative to market cap.

$ATRANeutralLow confidence
Context

Director Brian Cherry purchased 104,166 shares while ATRA stock surged 81% over six months.

Expected impact

Limited impact; price already elevated.

Evidence & confidence

Buy may reflect personal stake, but stock appears overvalued per analysis.

$SMIDBullishMedium confidence
Context

CEO Ashley Smith bought 2,000 shares as SMID trades near its 52‑week low.

Expected impact

Potential short‑term support.

Evidence & confidence

Buy size is small; impact limited unless more purchases follow.

$ILMNBearishMedium confidence
Context

Director Keith Meister sold $57.2 M of ILMN shares near its 52‑week high.

Expected impact

Possible short‑term downside.

Evidence & confidence

Large sale size relative to holdings may signal concerns.

$CRISNeutralLow confidence
Context

President David Baxley Spetzler sold $14.8 M of CRIS shares while the stock trades at $25.07.

Expected impact

Limited effect; market already pricing in performance.

Evidence & confidence

Sell size modest; broader market sentiment dominates.

$OKTABearishMedium confidence
Context

CFO Brett Tighe sold 80,000 OKTA shares under a 10b5‑1 plan near its 52‑week high.

Expected impact

Potential short‑term pullback.

Evidence & confidence

Sizeable sale but planned; may not reflect new information.

$KRYSNeutralLow confidence
Context

President/CEO Krish Krishnan sold 25,900 KRYS shares after a 139% gain year‑to‑date.

Expected impact

Minor short‑term pressure.

Evidence & confidence

Sell aligns with typical profit‑taking after large rally.

Market effects

Healthcare and tech insiders' activity may influence sector sentiment.

U.S. market focus; no broader regional effect.

Limited to U.S. listed companies.

Counterpoint

Insider sells may be routine profit‑taking, not a bearish signal.

Key entities

  • Enovis Corp.

    Medical device maker with recent insider purchases.

  • Illumina

    Genomics firm with a large insider sell.

Related articles

$SMIDMed

Smith-Midland Reports Third Quarter 2026 Financial Results

SMITH MIDLAND CORP (SMID) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Smith-Midland Reports Third Quarter 2026 Financial Results Record Backlog of $72.4 Million, Up 26% Sequentially and 32% Year-Over-Year MIDLAND, VA – November 16, 2026 – Smith-Midland Corporation (NASDAQ: SMID), a provider of innovative, high-quality proprietary and p

$CRISHigh

Curis Provides Third Quarter 2026 Business Update

CURIS INC (CRIS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Curis Provides Third Quarter 2026 Business Update Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., November 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of

$CRISMed

Curis (CRIS) Q3 2026 Earnings Call Transcript

Curis (CRIS) reported Q3 2026 net loss of $8.1M, narrower than 2025. The company is advancing clinical trials for emavusertib in NHL and CLL, with initial data expected by year-end. They aim for accelerated approval submissions in 2027. Cash reserves are $5M, expected to fund operations into 2027.

$CRISMedAI 8/10

Curis Provides Third Quarter 2026 Business Update

Curis, Inc. (CRIS) reported Q3 2026 financial results, showing a net loss of $8.1M, and provided a business update. The company is conducting studies on emavusertib for CLL and PCNSL, with initial data expected in December 2026. Curis completed a public offering and a private placement, extending its cash runway into 2027. Management will host a conference call to discuss the update.